239 related articles for article (PubMed ID: 10832450)
21. Additional mechanisms of nafamostat mesilate-associated hyperkalaemia.
Ookawara S; Tabei K; Sakurai T; Sakairi Y; Furuya H; Asano Y
Eur J Clin Pharmacol; 1996; 51(2):149-51. PubMed ID: 8911880
[TBL] [Abstract][Full Text] [Related]
22. Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Murakawa M; Okamura T; Shibuya T; Harada M; Otsuka T; Niho Y
Ann Hematol; 1992 May; 64(5):249-52. PubMed ID: 1623061
[TBL] [Abstract][Full Text] [Related]
23. [Effective use of camostat mesilate for chronic disseminated intravascular coagulation complicated by thoracoabdominal aortic aneurysm].
Yoneda K; Amano I; Tanaka H; Yagi H; Tsukaguchi N; Morii T; Narita N
Rinsho Ketsueki; 2001 Jan; 42(1):30-4. PubMed ID: 11235131
[TBL] [Abstract][Full Text] [Related]
24. Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis.
Lee JK; Ryu JK; Park JK; Lee SH; Yoon WJ; Kim YT; Jung HC; Yoon YB
Pancreas; 2008 Apr; 36(3):255-60. PubMed ID: 18362838
[TBL] [Abstract][Full Text] [Related]
25. Low-volume continuous hemodiafiltration with nafamostat mesilate increases trypsin clearance without decreasing plasma trypsin concentration in severe acute pancreatitis.
Okita Y; Okahisa T; Sogabe M; Suzuki M; Ohnishi Y; Ito S
ASAIO J; 2007; 53(2):207-12. PubMed ID: 17413562
[TBL] [Abstract][Full Text] [Related]
26. Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice.
Suzuki M; Isaji S; Stanten R; Frey CF; Ruebner B
Int J Pancreatol; 1992 Feb; 11(1):59-65. PubMed ID: 1374785
[TBL] [Abstract][Full Text] [Related]
27. [Effect of nafamostat mesilate on serum activities of pancreatic enzymes and plasma hormone levels].
Wakayama S; Suzuki T; Sakai T; Matsuki A
Masui; 1990 Jun; 39(6):734-40. PubMed ID: 2388392
[TBL] [Abstract][Full Text] [Related]
28. Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis.
Gabryelewicz A; Prokopowicz J; Bodzenta A; Bielecki W; Rydzewska G
Digestion; 1988; 40(1):19-24. PubMed ID: 3234615
[TBL] [Abstract][Full Text] [Related]
29. [The inhibitory effect of nafamostat mesilate (FUT-175) on liver metastasis].
Kimura T; Fuchimoto S; Iwagaki H; Orita K
Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):66-70. PubMed ID: 8437554
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system.
Hitomi Y; Ikari N; Fujii S
Haemostasis; 1985; 15(3):164-8. PubMed ID: 3161808
[TBL] [Abstract][Full Text] [Related]
31. The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat.
Wisner JR; Ozawa S; Renner IG
Int J Pancreatol; 1989 May; 4(4):383-90. PubMed ID: 2732529
[TBL] [Abstract][Full Text] [Related]
32. [Effect of nafamostat mesilate on the renin-aldosterone system].
Okamoto T; Marukawa S; Hayami H; Ozaki K; Ishida H; Kono K
Masui; 1992 Mar; 41(3):326-30. PubMed ID: 1560570
[TBL] [Abstract][Full Text] [Related]
33. Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress.
Marotta F; Fesce E; Rezakovic I; Chui DH; Suzuki K; Idéo G
Int J Pancreatol; 1994 Aug; 16(1):51-9. PubMed ID: 7528762
[TBL] [Abstract][Full Text] [Related]
34. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity.
Uchiba M; Okajima K; Abe H; Okabe H; Takatsuki K
Thromb Res; 1994 Apr; 74(2):155-61. PubMed ID: 8029816
[TBL] [Abstract][Full Text] [Related]
35. Hepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate.
Beckh K; Weidenbach H; Weidenbach F; Müller R; Adler G
Int J Pancreatol; 1991; 10(3-4):197-205. PubMed ID: 1787334
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of disseminated intravascular coagulation (DIC) or pre-DIC with gabexate mesilate (FOY)].
Wada H; Suzuki H; Mori Y; Deguchi A; Oukubo I; Tsuda M; Tanaka I; Deguchi K; Shirakawa S; Minami N
Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):67-73. PubMed ID: 3132518
[No Abstract] [Full Text] [Related]
37. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis.
Taenaka N; Shimada Y; Hirata T; Nishijima MK; Takezawa J; Yoshiya I; Kambayashi J
Crit Care Med; 1983 Sep; 11(9):735-8. PubMed ID: 6411432
[TBL] [Abstract][Full Text] [Related]
38. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of nafamostat mesilate on the performance of a hybrid-artificial liver using a polyurethane foam/porcine hepatocyte spheroid culture system in human plasma.
Yamashita Y; Shimada M; Tsujita E; Rikimaru T; Ijima H; Nakazawa K; Sakiyama R; Fukuda J; Funatsu K; Sugimachi K
Int J Artif Organs; 2001 Jan; 24(1):34-40. PubMed ID: 11266040
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic plasmapheresis for post-operative hepatic failure.
Tani T; Endo Y; Yoshioka T; Aoki H; Matsuda K; Numa K; Hanasawa K; Kodama M
Prog Clin Biol Res; 1990; 337():213-20. PubMed ID: 2352979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
